A Phase 1 Trial of Orca-Q
Phase 1
300
about 8.7 years
12–78
9 sites in CA, FL, GA +4
Why this study is shown
What this study is about
This trial is testing the safety and how well Orca-Q works in people who are getting a bone marrow transplant for leukemia, mixed phenotype acute leukemia, or myelodysplastic syndromes. The treatment type is biological medication.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive OrcaGraft (Orca-Q)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: Disease-free Survival (DFS) through Day +365, GVHD-free and Relapse-free Survival (GRFS) through Day +365, Overall Survival through Day +365
Oncology